This position statement emphasizes the high prevalence and negative prognostic impact of metabolic syndrome in hypertensive patients, recommending prompt lifestyle and pharmacological interventions.
Answers are grounded in this paper and cite their sources.
Clinicians should screen hypertensive patients for metabolic syndrome and treat aggressively; extends cardiometabolic guidelines with quantified prevalence.
Arterial hypertension is often part of a larger constellation of anthropometric and metabolic abnormalities that includes abdominal (or visceral) obesity, characteristic dyslipidemia (low high-density lipoprotein cholesterol and high triglycerides), glucose intolerance, insulin resistance and hyperuricemia. Using Adult Treatment Panel III criteria, prevalence is higher than in the general population and the metabolic syndrome (MS) can be found in as many as one third of patients. In hypertensives with MS, a high prevalence of hypertension-induced target organ damage and a negative prognostic value have been described. Dietary advice and life style changes should be strongly recommended and prompt pharmacologic treatment is required to control high blood pressure and to reduce risk. The effect of particular antihypertensive drugs on other components of the MS is an important clinical issue with consequences for the success of the treatment.
No takes yet. Share an insight, caveat, or question.
Redón et al. (2009) conducted a review in Hypertension and metabolic syndrome. Dietary advice, lifestyle changes, and pharmacologic treatment was evaluated. The metabolic syndrome is present in up to one third of hypertensive patients, requiring prompt lifestyle changes and pharmacologic treatment to control blood pressure and reduce risk.
Synapse has enriched 10 related papers. Consider them for comparative context: